About FOL026

FOL026 is a peptide-based drug candidate for the treatment of cardiovascular diseases. FOL026 has been developed to be injected into the blood, so that the whole body is affected. Our studies have shown that FOL026 can repair damaged vessel walls and also protect the vessel wall against stress (risk factors such as high blood pressure, high blood fats and diabetes).

The market

Cardiovascular disease is the largest cause of death worldwide and damage to the vessel wall is the most important cause of heart attacks and strokes. In 2023 alone, the diagnoses have been estimated to as many as 75 million cases worldwide.

There are no drugs on the market today that can help repair the vessel walls, as we have seen FOL026 do

The global myocardial infarction market size was valued at 1.9 billion US dollars in 2022, growing at a CAGR of 6.8% from 2022 to 2032, and is expected to reach 3.7 billion US dollars by 2032.

Market size

USD 1.9 billion

Milestones

2024

New research results.

2025

Establishing license agreement with partner.

Research

FOL026 protects against injury caused by high blood levels of glucose and lipids (glucolipotoxicity), stimulate vascular repair and the formation of new blood vessels, and stimulate muscular repair. FOL026 binds specifically to neuropilin-1, activating biological responses like those of the vascular endothelial growth factor (VEGF) family that are critical for formation and maintenance of blood vessels, and revitalization of tissue, processes that are crucial to treat myocardial infarction.

Osteopontin

FOL026

Plan

The plan is to continue research collaboration with Lunds University, and identify separate financing (e.g. through venture capital, licensing agreements etc.) during 2024 prior to finalizing the product formulation and initiation of the preclinical testing phase.

We are aiming to complete pre-clinical proof-of-concept and toxicology and First-in-Human studies within a timeframe of 3 years.